107 related articles for article (PubMed ID: 9363321)
1. The possible role of zinc and metallothionein in the liver on the therapeutic effect of IFN-alpha to hepatitis C patients.
Nagamine T; Takagi H; Hashimoto Y; Takayama H; Shimoda R; Nomura N; Suzuki K; Mori M; Nakajima K
Biol Trace Elem Res; 1997; 58(1-2):65-76. PubMed ID: 9363321
[TBL] [Abstract][Full Text] [Related]
2. Preliminary study of combination therapy with interferon-alpha and zinc in chronic hepatitis C patients with genotype 1b.
Nagamine T; Takagi H; Takayama H; Kojima A; Kakizaki S; Mori M; Nakajima K
Biol Trace Elem Res; 2000; 75(1-3):53-63. PubMed ID: 11051596
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha-induced changes in metallothionein expression in liver biopsies from patients with chronic hepatitis C.
Nagamine T; Suzuki K; Kondo T; Nakazato K; Kakizaki S; Takagi H; Nakajima K
Can J Gastroenterol; 2005 Aug; 19(8):481-6. PubMed ID: 16107899
[TBL] [Abstract][Full Text] [Related]
4. Interferon alpha induction of metallothionein in rat liver is not linked to interleukin-1, interleukin-6, or tumor necrosis factor alpha.
Guevara-Ortiz JM; Omar-Castellanos V; León-Chávez BA; Achanzar WE; Brambila E
Exp Mol Pathol; 2005 Aug; 79(1):33-8. PubMed ID: 16005709
[TBL] [Abstract][Full Text] [Related]
5. The effect of zinc supplementation on the treatment of chronic hepatitis C patients with interferon and ribavirin.
Ko WS; Guo CH; Hsu GS; Chiou YL; Yeh MS; Yaun SR
Clin Biochem; 2005 Jul; 38(7):614-20. PubMed ID: 15904908
[TBL] [Abstract][Full Text] [Related]
6. Role of serum soluble Fas/soluble Fas ligand and TNF-alpha on response to interferon-alpha therapy in chronic hepatitis C.
Toyoda M; Kakizaki S; Horiguchi N; Sato K; Takayama H; Takagi H; Nagamine T; Mori M
Liver; 2000 Jul; 20(4):305-11. PubMed ID: 10959809
[TBL] [Abstract][Full Text] [Related]
7. Hepatic metallothionein in patients with chronic hepatitis C: relationship with severity of liver disease and response to treatment.
Carrera G; Paternain JL; Carrere N; Folch J; Courtade-Saïdi M; Orfila C; Vinel JP; Alric L; Pipy B
Am J Gastroenterol; 2003 May; 98(5):1142-9. PubMed ID: 12809840
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha receptor 1 mRNA expression in peripheral blood mononuclear cells is associated with response to interferon-alpha therapy of patients with chronic hepatitis C.
Massirer KB; Hirata MH; Silva AE; Ferraz ML; Nguyen NY; Hirata RD
Braz J Med Biol Res; 2004 May; 37(5):643-7. PubMed ID: 15107924
[TBL] [Abstract][Full Text] [Related]
9. Natural interferon alpha treatment and interferon alpha receptor 2 levels in acute hepatitis C.
Ohata K; Yano K; Yatsuhashi H; Daikoku M; Koga M; Eguchi K; Yano M
Dig Dis Sci; 2004 Feb; 49(2):289-94. PubMed ID: 15104372
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C.
Karino Y; Toyota J; Sugawara M; Miyazaki K; Kuwata Y; Yamazaki K; Sato T; Ohmura T; Matsushima T
J Gastroenterol Hepatol; 2003 Apr; 18(4):404-10. PubMed ID: 12653888
[TBL] [Abstract][Full Text] [Related]
11. Serum copper and zinc concentrations in patients with chronic hepatitis C.
Cesur S; Cebeci SA; Kavas GO; Yilmaz N; Buyukkagnici DI
J Infect; 2005 Jul; 51(1):35-7. PubMed ID: 15979488
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of soluble interferon Alfa/Beta receptor as an inhibitory factor of interferon in the patients with chronic hepatitis C.
Mizukoshi E; Kaneko S; Kaji K; Terasaki S; Matsushita E; Muraguchi M; Ohmoto Y; Kobayashi K
Hepatology; 1999 Nov; 30(5):1325-31. PubMed ID: 10534358
[TBL] [Abstract][Full Text] [Related]
13. Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha.
Alvarado Esquivel C; Elewaut A; Philippé J; Elewaut AE; Desombere I; Maertens G; Leroux-Roels G
Rev Invest Clin; 2002; 54(1):41-50. PubMed ID: 11995406
[TBL] [Abstract][Full Text] [Related]
14. Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha.
Lebensztejn DM; Sobaniec-Lotowska ME; Kaczmarski M; Voelker M; Schuppan D
World J Gastroenterol; 2006 Jun; 12(21):3338-43. PubMed ID: 16733849
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of ursodeoxycholic acid in association with alpha-interferon for chronic hepatitis C in alpha-interferon non-responder patients.
Fabbri C; Marchetto S; Pezzoli A; Accogli E; Fusaroli P; Azzaroli F; Jaboli MF; Mazzeo C; Montagnani M; Festi D; Roda E; Mazzella G
Eur J Gastroenterol Hepatol; 2000 May; 12(5):511-5. PubMed ID: 10833093
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of hepatic interferon alpha-beta receptor level: relationship between receptor expression and response to interferon therapy in patients with chronic hepatitis C.
Yatsuhashi H; Fujino T; Matsumoto T; Inoue O; Koga M; Yano M
J Hepatol; 1999 Jun; 30(6):995-1003. PubMed ID: 10406176
[TBL] [Abstract][Full Text] [Related]
17. [Impact of interferon alpha immunotherapy on tryptophan metabolism in patients with chronic hepatitis C. Results of a pilot studies on ten patients].
Vignau J; Costisella O; Canva V; Imbenotte M; Duhamel A; Lhermitte M
Encephale; 2009 Oct; 35(5):477-83. PubMed ID: 19853722
[TBL] [Abstract][Full Text] [Related]
18. Paradoxical alteration of acute-phase protein levels in patients with chronic hepatitis C treated with IFN-alpha2b.
Kalabay L; Nemesánszky E; Csepregi A; Pusztay M; Dávid K; Horváth G; Ibrányi E; Telegdy L; Pár A; Bíró A; Fekete B; Gervain J; Horányi M; Ribiczey P; Csöndes M; Kleiber M; Walentin S; Prohászka Z; Füst G
Int Immunol; 2004 Jan; 16(1):51-4. PubMed ID: 14688060
[TBL] [Abstract][Full Text] [Related]
19. A new diagnostic method for chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma based on serum metallothionein, copper, and zinc levels.
Nakayama A; Fukuda H; Ebara M; Hamasaki H; Nakajima K; Sakurai H
Biol Pharm Bull; 2002 Apr; 25(4):426-31. PubMed ID: 11995918
[TBL] [Abstract][Full Text] [Related]
20. Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: a randomized controlled clinical trial.
Suzuki H; Takagi H; Sohara N; Kanda D; Kakizaki S; Sato K; Mori M;
World J Gastroenterol; 2006 Feb; 12(8):1265-9. PubMed ID: 16534882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
